Clinical Trial Update: Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating autologous T-cells genetically modified at the CCR5 gene using zinc finger nucleases in HIV-infected subjects has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Autologous T-cells genetically modified at the CCR5 gene by zinc finger nucleases

Snippet

Sponsor: Sangamo Therapeutics | Conditions: HIV, HIV Infection | Phase 1, Phase 2 | Status: COMPLETED